Eighteen months after it closed and stopped production, Nimbus Brewing Co.’s fan favorite Pale Ale and Blonde Ale are back on Arizona store shelves, and the signature Monkeyshine Ale is back on tap in ...
Ahead of the Harry Potter TV show, a new study revealed the franchise’s most valuable props. One iconic Wizarding World prop ...
Broomsticks are the primary mode of transport in Harry Potter‘s wizarding world and the backbone of its most popular sport, Quidditch. Not every broom is built for speed. Most are built for ...
Asics’ ‘comfort’ shoe returns with its latest model; a dependable and neutral running trainer that offers high support, cushion and bounce Lucy is a freelance journalist, specialising in health, ...
NEW YORK and TEL AVIV, Israel, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Nukkleus Inc. (NASDAQ: NUKK), a strategic acquirer and developer of high-potential businesses in the Aerospace and Defense (A&D) sector ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Jan 6 (Reuters) - Nimbus Therapeutics said on Tuesday it has entered into a multi-year research and licensing agreement with Eli Lilly (LLY.N), opens new tab to develop artificial intelligence-driven ...
Boston biotech Nimbus Therapeutics is teaming up with Eli Lilly & Co. to develop a new oral obesity treatment in a deal worth up to $1.3 billion, the company announced Tuesday. It’s the latest move in ...
This morning’s announcement follows a 2022 deal worth up to $496 million in biobucks. (iStock/Getty Images Plus) Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this ...
For a second time, Eli Lilly has turned to Boston biotech Nimbus Therapeutics to add a potential weight loss therapy to its pipeline. The latest agreement, which could be worth upwards of $1.3 billion ...
Nimbus and Eli Lilly collaborate to develop oral treatments for obesity and metabolic diseases, leveraging Nimbus' computational drug design and Lilly's metabolic expertise. The agreement includes $55 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results